Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database

CONCLUSION: HREM may be preferred for elderly patients (≥60 years) due to a lower risk of immune-related events like IRIS-TB, but requires careful liver monitoring. HREL could be an option for younger patients (<60 years), though vigilance for hepatotoxicity and IRIS-TB is needed, especially in females. For males on HREM, increased attention to neurological AEs is recommended.